Clinical and Radiological Heterogeneity in Anti‐Neurofascin‐155 Autoimmune Nodopathy: A Case Series Analysis
Journal of the Peripheral Nervous System · 2025
DOI: 10.1111/jns.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2025. Verfasst von Michie Imamura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Autoantibodies, Nerve Growth Factors, Autoimmune Diseases of the Nervous System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Background and Aims Autoimmune nodopathy with anti‐neurofascin‐155 (NF155) antibodies is increasingly recognized as a distinct disease entity. Although these patients have been described, not all aspects have been fully elucidated. We investigated clinical phenotypes, biomarker profiles, and treatment outcomes in patients with anti‐NF155 antibody‐positive autoimmune nodopathy.
Methods
We retrospectively analyzed seven Japanese patients (aged 13–27 years) with anti‐NF155 antibody‐positive autoimmune nodopathy treated at Kumamoto University Hospital between 2017 and 2020. Clinical, electrophysiological, radiological, and biomarker data were evaluated. One refractory case was followed up for over 80 months, tracking serum neurofilament light chain (sNfL) and anti‐NF155 antibody levels in the serum and cerebrospinal fluid (CSF).
Results
All patients exhibited severe sensory ataxia and motor dysfunction. Trigeminal nerve hypertrophy was observed in five individuals, without corresponding symptoms, and pes cavus in one patient. All patients demonstrated a pronounced demyelinating neuropathy phenotype. The mean CSF protein level was 343 mg/dL. Intravenous immunoglobulin (IVIg) had minimal efficacy, while corticosteroids produced good responses in four patients and partial responses in three patients. Rituximab markedly improved a refractory case. Anti‐NF155 antibody and sNfL levels correlated with clinical status. Magnetic resonance imaging frequently revealed persistent nerve root hypertrophy despite functional improvement.
Interpretation
Anti‐NF155 nodopathy is a distinct, biomarker‐trackable entity; corticosteroids and rituximab outperform IVIg, challenging conventional practice and highlighting the need for antibody testing, especially in young patients with severe demyelinating neuropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
ORCID-Profile: Hironori Mizutani, Noriko Isobe, Mitsuharu Ueda
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Imamura, M., Mizutani, H., Nakahara, K., Ogata, H., Taguchi, T., Imura, M., Nomura, T., Misumi, Y., Isobe, N., & Ueda, M. (2025). Clinical and Radiological Heterogeneity in Anti‐Neurofascin‐155 Autoimmune Nodopathy: A Case Series Analysis. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70077
Vancouver
Imamura M, Mizutani H, Nakahara K, Ogata H, Taguchi T, Imura M, et al. Clinical and Radiological Heterogeneity in Anti‐Neurofascin‐155 Autoimmune Nodopathy: A Case Series Analysis. Journal of the Peripheral Nervous System. 2025. doi:10.1111/jns.70077
BibTeX
@article{Imamura2025,
author = {Imamura, Michie and Mizutani, Hironori and Nakahara, Keiichi and Ogata, Hidenori and Taguchi, Tomoaki and Imura, Masao and Nomura, Toshiya and Misumi, Yohei and Isobe, Noriko and Ueda, Mitsuharu},
title = {Clinical and Radiological Heterogeneity in Anti‐Neurofascin‐155 Autoimmune Nodopathy: A Case Series Analysis},
journal = {Journal of the Peripheral Nervous System},
year = {2025},
doi = {10.1111/jns.70077}
}
EUVIMED